AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.
The Japan Agency for Medical Research and Development, created less than two months ago in the model of the U.S. NIH, is now ready to receive up to 200,000 substance samples from more than 10 drugmakers. In exchange for providing the substances free of charge, AMED said it would work with universities and other researchers to test a substance's use in treating various diseases and ailments, such as cancer and infection.
Medtronic, known mostly for its high-priced medical devices, is looking for some deals in China as it chases low-price customers for its line of "value products."
Mitsubishi Chemical Holdings unit Life Science Institute has bought multilineage-differentiating stress-enduring (Muse) stem cell firm Clio for more than 1 billion yen ($8 million), according to a press release. Life Sciences in a Japanese language release on May 14 said Clio will become a wholly-owned subsidiary.
BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.
Serum Institute of India and compatriot Cipla have inked a pact to market a flu vaccine.
Johnson & Johnson has established an outpost within Karolinska Institutet. The arrangement sees J&J set an innovation hub at the Swedish medical university, from which it will keep tabs on academic research breakthroughs and support the advance of such ideas into life science startups.
Singapore's research agency and Duke-National University of Singapore have signed an agreement to collaborate with U.S. biotech Visterra on getting a promising treatment against dengue fever to the clinical-trial stage.
Fast-track diagnostics will develop assays for use on Biocartis' Idylla testing platform, which searches for multiple pathogens following a single test, or what's known as syndromic multiplex testing.
Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.